Changing the Ecology of Pneumococci with Antibiotics and Vaccines

Ron Dagan; Marc Lipsitch

doi:10.1128/9781555816537.ch18

Chapter 18 : Changing the Ecology of Pneumococci with Antibiotics and Vaccines

VIEW AFFILIATIONS HIDE AFFILIATIONS

Affiliations: 1: Pediatric Infectious Disease Unit, Soroka University Medical Center, and Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 151, Beer-Sheva 84101, Israel; 2: Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115

Content Type: Monograph

Publication Year: 2004

Category: Bacterial Pathogenesis; Clinical Microbiology

Book DOI: 10.1128/9781555816537

Chapter DOI: 10.1128/9781555816537.ch18

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Changing the Ecology of Pneumococci with Antibiotics and Vaccines, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555816537/9781555812973_Chap18-1.gif /docserver/preview/fulltext/10.1128/9781555816537/9781555812973_Chap18-2.gif

Abstract:

This chapter describes the mechanisms and consequences for the pneumococcal population of the selective pressures imposed by antibiotics and vaccines. While inhibiting pneumococci can have effects on other species of upper respiratory tract (URT) bacteria, the chapter focuses on the selective effects of vaccines and antibiotics on pneumococci. The direct effects of antibiotics on S. pneumonia in the nasopharynx of the treated patient depend on the pharmacokinetics and pharmacodynamics of the agent. Streptococcus pneumoniae resistance to the beta-lactam antibiotic class evolved mainly by complex restructuring of the targets of the beta-lactams, the penicillin-binding proteins (PBPs). To summarize the effect of antibiotics on S. pneumoniae ecology, it is clear that antibiotic treatment in any community profoundly affects S. pneumoniae ecology. Furthermore, a significant reduction of carriage of antibiotic-resistant and multidrug resistant (MDR) S. pneumoniae in the younger siblings of the day care attendees as the result of vaccination of their older siblings was observed. The chapter emphasizes the effects of vaccines and antibiotics on the ecology of pneumococci taking place against a background of a genetically diverse population structured by direct and indirect ecological interactions between strains. The importance of understanding pneumococcal population structure has been appreciated since the earliest days. This understanding can be extended to reconcile the disparate results of clinical trials of antibiotics and vaccines, to evaluate the relative selective effect of different antibiotics for resistant strains, and to project the effects of vaccines and antibiotics on future patterns in the prevalence of serotypes and resistant strains.

Citation: Dagan R, Lipsitch M. 2004. Changing the Ecology of Pneumococci with Antibiotics and Vaccines, p 283-313. In Tuomanen E, Mitchell T, Morrison D, Spratt B (ed), The Pneumococcus. ASM Press, Washington, DC. doi: 10.1128/9781555816537.ch18

Key Concept Ranking

Pneumococcal Conjugate Vaccine: 0.6050163
Acute Otitis Media: 0.56855077
Antibacterial Agents: 0.51309043

0.6050163

Highlighted Text: Show | Hide

Full text loading...

Figures

Changing the Ecology of Pneumococci with Antibiotics and Vaccines

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555816537.chap18-1,webId=/content/author/10.1128/9781555816537.chap18-1,properties={foaf_givenname=Ron, foaf_name=Ron Dagan, foaf_surname=Dagan, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555816537.chap18-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555816537.chap18-2,webId=/content/author/10.1128/9781555816537.chap18-2,properties={foaf_givenname=Marc, foaf_name=Marc Lipsitch, foaf_surname=Lipsitch, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555816537.chap18-aff2]]}]]

/content/10.1128/9781555816537.chap18.fig18-1

FIGURE 1

Effect of treatment with various macrolides on the carriage of macrolide-resistant microorganisms in the throat 1 to 6 weeks after initiation of treatment ( 61 ). All children were treated for 7 days (except the azithromycin group, which was treated for 3 days). The median age of the children was 4.2 years, without a significant difference in age distribution between the group. P < 0.005 for azithromycin versus all other groups.

10.1128/9781555816537/fig18-1_thmb.gif

10.1128/9781555816537/fig18-1.gif

FIGURE 1

/content/10.1128/9781555816537.chap18.fig18-2

FIGURE 2

Nasopharyngeal carriage of TS-resistant and penicillin-nonsusceptible S. pneumoniae in children with acute otitis media treated with TS for 10 days (Dagan et al., 39th ICAAC, abstr. 1028). *, P = 0.038 day 1 versus all other days combined. **, P = 0.1 day 1 versus all other days combined.

10.1128/9781555816537/fig18-2_thmb.gif

10.1128/9781555816537/fig18-2.gif

FIGURE 2

/content/10.1128/9781555816537.chap18.fig18-3

FIGURE 3

Nasopharyngeal carriage of macrolide-resistant or MDR S. pneumoniaein children with acute otitis media treated with azithromycin for 5 days (Dagan et al., 43rd ICAAC, abstr. G-1856). *, P < 0.05 compared to day 1. **, P = 0.095 compared to day 1.

10.1128/9781555816537/fig18-3_thmb.gif

10.1128/9781555816537/fig18-3.gif

FIGURE 3

/content/10.1128/9781555816537.chap18.fig18-4

FIGURE 4

Nasopharyngeal carriage of macrolide-resistant and MDR S. pneumoniaein children with acute otitis media treated with azithromycin for 5 days in two periods: 1998 and 2001 to 2002 (Dagan et al., 43rd ICAAC, abstr. G-898). (A) Comparison of the effect of azithromycin on carriage of macrolide-resistant and MDR S. pneumoniae between 1998 and 2001 to 2002; (B) relation of macrolide resistance and MDR in S. pneumoniae isolated from middle ear fluid (MEF) in southern Israel in 1998 (n = 563), 2001 (n = 672), and 2002 (n = 639) (unpublished data).

10.1128/9781555816537/fig18-4_thmb.gif

10.1128/9781555816537/fig18-4.gif

FIGURE 4

/content/10.1128/9781555816537.chap18.fig18-5

FIGURE 5

S. pneumoniae nasopharyngeal carriage in children treated with high-dose amoxicillin-clavulanate for 10 days versus 5 days of azithromycin for acute otitis media, by susceptibility to penicillin, susceptibility to erythromycin, and MDR. Pen, penicillin; ERY, erythromycin; hA/C, high-dose amoxicillin-clavulanate; AZI, azithromycin; D, day; S, susceptible; R, resistant.

10.1128/9781555816537/fig18-5_thmb.gif

10.1128/9781555816537/fig18-5.gif

FIGURE 5

/content/10.1128/9781555816537.chap18.fig18-6

FIGURE 6

Effect of PnCRM7 ( 39 ) and PnOMPC7 ( 65 ) in prevention of acute otitis media caused by VT S. pneumoniae, VT-related S. pneumoniae, non-VT S. pneumoniae, H. influenzae, and M. catarrhalis. Positive values represent a reduction in episodes; negative values represent an increase in cases.

10.1128/9781555816537/fig18-6_thmb.gif

10.1128/9781555816537/fig18-6.gif

FIGURE 6

/content/10.1128/9781555816537.chap18.fig18-7

FIGURE 7

Number of pneumococcal acute otitis media episodes caused by VT (PNCV) and non-VT S. pneumoniae at the Children's Hospital of Pittsburgh from 1 January 1999 to 31 December 2002 (McEllistrem et al., 43rd ICAAC, abstr. G-2047). The arrow indicates the start of widespread vaccination with PnCRM7 in the United States.

10.1128/9781555816537/fig18-7_thmb.gif

10.1128/9781555816537/fig18-7.gif

FIGURE 7

/content/10.1128/9781555816537.chap18.fig18-8

FIGURE 8

Distribution of VT (serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F), serotype 6A, non-VT pneumococci (all other serotypes), and no growth in 149 cultures from 23 younger siblings of day care center (DCC) attendees receiving PnCRM9 and 157 cultures from 23 younger siblings of the control group. This was compared with 1,886 cultures from the 132 older DCC attendee recipients of the PnCRM9 vaccine and 1,862 cultures from 130 DCC attendees receiving control vaccines.

10.1128/9781555816537/fig18-8_thmb.gif

10.1128/9781555816537/fig18-8.gif

FIGURE 8

/content/10.1128/9781555816537.chap18.fig18-9

FIGURE 9

National trends in antibiotic-resistant invasive pneumococcal disease in the conjugate-vaccine era in the United States after the introduction of PnCRM7 to infants and toddlers in 2000 (Kyaw et al., 43rd ICAAC, abstr. G-2045). The reduction figures are for comparison of 2002 to 1999. (A) Penicillin, macrolide, and penicillin plus macrolide nonsusceptibility in children 2 years of age; (B) penicillin nonsusceptibility in children aged 2 to 4 years and adults aged 20 to 39 years and ≥65 years. Pen, penicillin; Macro, macrolides; NS, nonsusceptible.

10.1128/9781555816537/fig18-9_thmb.gif

10.1128/9781555816537/fig18-9.gif

FIGURE 9

References

/content/book/10.1128/9781555816537.chap18

1. Andersson, D. I. 2003. Persistence of antibiotic resistant bacteria. Curr. Opin. Microbiol. 6: 452– 456.

2. Arason, V. A.,, K. G. Kristinsson,, J. A. Sigurdsson,, G. Stefansdottir,, S. Molstad,, and S. Gudmundsson. 1996. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ 313: 387– 391.

3. Arnold, K. E.,, R. J. Leggiadro,, R. F. Breiman,, H. B. Lipman,, B. Schwartz,, M. A. Appleton,, K. O. Cleveland,, H. C. Szeto,, B. C. Hill,, F. C. Tenover,, J. A. Elliott,, and R. R. Facklam. 1996. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J. Pediatr. 128: 757– 764.

4. Austrian, R. 1986. Some aspects of the pneumococcal carrier state. J. Antimicrob. Chemother. 18( Suppl. A): 35– 45.

5. Baquero, F. 1999. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J. Chemother. 11( Suppl. 1): 35– 43.

6. Baquero, F. 1995. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb. Drug Resist. 1: 115– 120.

7. Barbour, M. L.,, R. T. Mayon-White,, C. Coles,, D. W. Crook,, and E. R. Moxon. 1995. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J. Infect. Dis. 171: 93– 98.

8. Batt, S. L.,, B. M. Charalambous,, A. W. Solomon,, C. Knirsch,, P. A. Massae,, S. Safari,, N. E. Sam,, D. Everett,, D. C. Mabey,, and S. H. Gillespie. 2003. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 2765– 2769.

9. Beall, B.,, M. C. McEllistrem,, R. E. Gertz, Jr.,, D. J. Boxrud,, J. M. Besser,, L. H. Harrison,, J. H. Jorgensen,, and C. G. Whitney. 2002. Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of Streptococcus pneumoniae within the United States. J. Infect. Dis. 186: 118– 122.

10. Black, S.,, H. Shinefield,, B. Fireman,, E. Lewis,, P. Ray,, J. R. Hansen,, L. Elvin,, K. M. Ensor,, J. Hackell,, G. Siber,, F. Malinoski,, D. Madore,, I. Chang,, R. Kohberger,, W. Watson,, R. Austrian,, and K. Edwards. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19: 187– 195.

11. Black, S. B.,, H. R. Shinefield,, S. Ling,, J. Hansen,, B. Fireman,, D. Spring,, J. Noyes,, E. Lewis,, P. Ray,, J. Lee,, and J. Hackell. 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21: 810– 815.

12. Boken, D. J.,, S. A. Chartrand,, E. S. Moland,, and R. V. Goering. 1996. Colonization with penicillin-nonsusceptible Streptococcus pneumoniae in urban and rural child-care centers. Pediatr. Infect. Dis. J. 15: 667– 672.

13. Briles, D. E.,, E. Ades,, J. C. Paton,, J. S. Sampson,, G. M. Carlone,, R. C. Huebner,, A. Virolainen,, E. Swiatlo,, and S. K. Hollingshead. 2000. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 68: 796– 800.

14. Briles, D. E.,, S. K. Hollingshead,, G. S. Nabors,, J. C. Paton,, and A. Brooks-Walter. 2000. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19( Suppl. 1): S87– S95.

15. Bronzwaer, S. L.,, O. Cars,, U. Buchholz,, S. Molstad,, W. Goettsch,, I. K. Veldhuijzen,, J. L. Kool,, M. J. Sprenger,, and J. E. Degener. 2002. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg. Infect. Dis. 8: 278– 282.

16. Brook, I. 2001. The role of beta-lactamase producing bacteria and bacterial interference in streptococcal tonsillitis. Int. J. Antimicrob. Agents 17: 439– 442.

17. Brook, I.,, and A. E. Gober. 1996. Prophylaxis with amoxicillin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacteria from children. Clin. Infect. Dis. 22: 143– 145.

18. Brueggemann, A. B.,, D. T. Griffiths,, E. Meats,, T. Peto,, D. W. Crook,, and B. G. Spratt. 2003. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J. Infect. Dis. 187: 1424– 1432.

19. Chambers, H. F. 1999. Penicillin-binding protein- mediated resistance in pneumococci and staphylococci. J. Infect. Dis. 179( Suppl. 2): S353– S359.

20. Chen, D. K.,, A. McGeer,, J. C. de Azavedo,, D. E. Low, and Canadian Bacterial Surveillance Network. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341: 233– 239.

21. Cohen, R.,, E. Bingen,, E. Varon,, F. de La Rocque,, N. Brahimi,, C. Levy,, M. Boucherat,, J. Langue,, and P. Geslin. 1997. Change in nasopharyngeal carriage of Streptococcus pneumoniae resulting from antibiotic therapy for acute otitis media in children. Pediatr. Infect. Dis. J. 16: 555– 560.

22. Cohen, R.,, M. Navel,, J. Grunberg,, M. Boucherat,, P. Geslin,, M. Derriennic,, F. Pichon,, and J. M. Goehrs. 1999. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora. Pediatr. Infect. Dis. J. 18: 403– 409.

23. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26: 1– 10.

24. Craig, W. A.,, and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15: 255– 259.

25. Dabernat, H.,, P. Geslin,, F. Megraud,, P. Begue,, J. Boulesteix,, C. Dubreuil,, F. de La Roque,, A. Trinh,, and A. Scheimberg. 1998. Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. J. Antimicrob. Chemother. 41: 253– 258.

26. Dagan, R.,, N. Givon-Lavi,, L. Shkolnik,, P. Yagupsky,, and D. Fraser. 2000. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. J. Infect. Dis. 181: 1322– 1329.

27. Dagan, R.,, N. Givon-Lavi,, O. Zamir,, and D. Fraser. 2003. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr. Infect. Dis. J. 22: 532– 540.

28. Dagan, R.,, N. Givon-Lavi,, O. Zamir,, M. Sikuler-Cohen,, L. Guy,, J. Janco,, P. Yagupsky,, and D. Fraser. 2002. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185: 927– 936.

29. Dagan, R.,, E. Leibovitz,, D. Greenberg,, P. Yagupsky,, D. M. Fliss,, and A. Leiberman. 1998. Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients. Pediatr. Infect. Dis. J. 17: 880– 885.

30. Dagan, R.,, R. Melamed,, M. Muallem,, L. Piglansky,, D. Greenberg,, O. Abramson,, P. M. Mendelman,, N. Bohidar,, and P. Yagupsky. 1996. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 174: 1271– 1278.

31. Dagan, R.,, R. Melamed,, M. Muallem,, L. Piglansky,, and P. Yagupsky. 1996. Nasopharyngeal colonization in southern Israel with antibiotic- resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J. Infect. Dis. 174: 1352– 1355.

32. Dagan, R.,, M. Muallem,, R. Melamed,, O. Leroy,, and P. Yagupsky. 1997. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr. Infect. Dis. J. 16: 1060– 1064.

33. Dagan, R.,, M. Sikuler-Cohen,, O. Zamir,, J. Janco,, N. Givon-Lavi,, and D. Fraser. 2001. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr. Infect. Dis. J. 20: 951– 958.

34. De Lencastre, H.,, K. G. Kristinsson,, A. Brito-Avo,, I. S. Sanches,, R. Sa-Leao,, J. Saldanha,, E. Sigvaldadottir,, S. Karlsson,, D. Oliveira,, R. Mato,, M. Aires de Sousa,, and A. Tomasz. 1999. Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae colonization in healthy children attending day care centers in Lisbon, Portugal. Microb. Drug Resist. 5: 19– 29.

35. den Hollander, J. G.,, J. D. Knudsen,, J. W. Mouton,, K. Fuursted,, N. Frimodt-Moller,, H. A. Verbrugh,, and F. Espersen. 1998. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob. Agents Chemother. 42: 377– 382.

36. Diekema, D. J.,, A. B. Brueggemann,, and G. V. Doern. 2000. Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae. Emerg. Infect. Dis. 6: 552– 556.

37. Drusano, G. L.,, and W. A. Craig. 1997. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J. Chemother. 9( Suppl. 3): 38– 44.

38. Eskola, J.,, S. Black,, and H. Shinefield,. 2003. Pneumococcal conjugate vaccines, p. 589– 624. In S. A. Plotkin, and M. D. Orenstein (ed.), Vaccines, 4th ed. W. B. Saunders Company, Philadelphia, Pa.

39. Eskola, J.,, T. Kilpi,, A. Palmu,, J. Jokinen,, J. Haapakoski,, E. Herva,, A. Takala,, H. Kayhty,, P. Karma,, R. Kohberger,, G. Siber,, and P. H. Makela. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344: 403– 409.

40. Feikin, D. R.,, S. F. Dowell,, O. C. Nwanyanwu,, K. P. Klugman,, P. N. Kazembe,, L. M. Barat,, C. Graf,, P. B. Bloland,, C. Ziba,, R. E. Huebner,, and B. Schwartz. 2000. Increased carriage of trimethoprim/ sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J. Infect. Dis. 181: 1501– 1505.

41. Fenoll, A.,, I. Jado,, D. Vicioso,, A. Perez,, and J. Casal. 1998. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J. Clin. Microbiol. 36: 3447– 3454.

42. Finland, M.,, and M. W. Barnes. 1977. Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974. J. Clin. Microbiol. 5: 154– 166.

43. Fireman, B.,, S. B. Black,, H. R. Shinefield,, J. Lee,, E. Lewis,, and P. Ray. 2003. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22: 10– 16.

44. Garcia-Rey, C.,, L. Aguilar,, F. Baquero,, J. Casal,, and R. Dal-Re. 2002. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J. Clin. Microbiol. 40: 159– 164.

45. Ghaffar, F.,, L. S. Muniz,, K. Katz,, J. Reynolds,, J. L. Smith,, P. Davis,, I. R. Friedland,, and G. H. McCracken, Jr. 2000. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Clin. Infect. Dis. 31: 875– 880.

46. Ghaffar, F.,, L. S. Muniz,, K. Katz,, J. L. Smith,, T. Shouse,, P. Davis,, and G. H. Mc- Cracken, Jr. 2002. Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal alpha-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media. Clin. Infect. Dis. 34: 1301– 1309.

47. Gillespie, S. H.,, L. L. Voelker,, and A. Dickens. 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb. Drug Resist. 8: 79– 84.

48. Givon-Lavi, N.,, R. Dagan,, D. Fraser,, P. Yagupsky,, and N. Porat. 1999. Marked differences in pneumococcal carriage and resistance patterns between day care centers located within a small area. Clin. Infect. Dis. 29: 1274– 1280.

49. Givon-Lavi, N.,, D. Fraser,, and R. Dagan. 2003. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr. Infect. Dis. J. 22: 524– 532.

50. Griffith, F. 1928. The significance of pneumococcal types. J. Hyg. 27: 8– 159.

51. Guillemot, D.,, C. Carbon,, B. Balkau,, P. Geslin,, H. Lecoeur,, F. Vauzelle- Kervroedan,, G. Bouvenot,, and E. Eschwege. 1998. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279: 365– 370.

52. Gundel, M.,, and G. Okura. 1933. Untersuchungen uber das gleichzeitige Vorkommen mehrerer Pneumokokkentypen bei Gesunden und ihre Bedeutung für die Epidemiologie. Z. Hyg. Infektionskr. 114: 678– 704.

53. Haiman, T.,, E. Leibovitz,, L. Piglansky,, J. Press,, P. Yagupsky,, A. Leiberman,, and R. Dagan. 2002. Dynamics of pneumococcal nasopharyngeal carriage in children with nonresponsive acute otitis media treated with two regimens of intramuscular ceftriaxone. Pediatr. Infect. Dis. J. 21: 642– 647.

54. Hakenbeck, R.,, T. Grebe,, D. Zahner,, and J. B. Stock. 1999. Beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol. Microbiol. 33: 673– 678.

55. Hausdorff, W. P.,, J. Bryant,, C. Kloek,, P. R. Paradiso,, and G. R. Siber. 2000. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin. Infect. Dis. 30: 122– 140.

56. Hausdorff, W. P.,, J. Bryant,, P. R. Paradiso,, and G. R. Siber. 2000. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30: 100– 121.

57. Heikkinen, T. 2000. Role of viruses in the pathogenesis of acute otitis media. Pediatr. Infect. Dis. J. 19: S17– 22.

58. Hyde, T. B.,, K. Gay,, D. S. Stephens,, D. J. Vugia,, M. Pass,, S. Johnson,, N. L. Barrett,, W. Schaffner,, P. R. Cieslak,, P. S. Maupin,, E. R. Zell,, J. H. Jorgensen,, R. R. Facklam,, and C. G. Whitney. 2001. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286: 1857– 1862.

59. Jacobs, M. R.,, D. Felmingham,, P. C. Appelbaum,, and R. N. Gruneberg. 2003. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52: 229– 246.

60. Jones, R. N.,, A. H. Mutnick,, and D. J. Varnam. 2002. Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001). J. Clin. Microbiol. 40: 4332– 4333.

61. Kastner, U.,, and J. P. Guggenbichler. 2001. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection 29: 251– 256.

62. Kauppi, M.,, J. Eskola,, and H. Kayhty. 1995. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr. Infect. Dis. J. 14: 286– 294.

63. Kellner, J. D.,, E. L. Ford-Jones, and Toronto Child Care Centre Study Group. 1999. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Arch. Pediatr. Adolesc. Med. 153: 495– 502.

64. Kilian, M.,, J. Reinholdt,, H. Lomholt,, K. Poulsen,, and E. V. Frandsen. 1996. Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. APMIS 104: 321– 338.

65. Kilpi, T.,, H. Ahman,, J. Jokinen,, K. S. Lankinen,, A. Palmu,, H. Savolainen,, M. Gronholm,, M. Leinonen,, T. Hovi,, J. Eskola,, H. Kayhty,, N. Bohidar,, J. C. Sadoff,, and P. H. Makela. 2003. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37: 1155– 1164.

66. Klugman, K. P.,, S. A. Madhi,, R. E. Huebner,, R. Kohberger,, N. Mbelle,, and N. Pierce. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349: 1341– 1348.

67. Korkeila, M.,, H. Lehtonen,, H. Ahman,, O. Leroy,, J. Eskola,, and H. Kayhty. 2000. Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid. Vaccine 18: 1218– 1226.

68. Lenski, R. E.,, and S. E. Hattingh. 1986. Coexistence of two competitors on one resource and one inhibitor: a chemostat model based on bacteria and antibiotics. J. Theor. Biol. 122: 83– 93.

69. Lipsitch, M. 1999. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg. Infect. Dis. 5: 336– 345.

70. Lipsitch, M. 2001. Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin. Infect. Dis. 32: 1044– 1054.

71. Lipsitch, M. 2001. The rise and fall of antimicrobial resistance. Trends Microbiol. 9: 438– 444.

72. Lipsitch, M.,, and M. H. Samore. 2002. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg. Infect. Dis. 8: 347– 354.

73. Mackowiak, P. A. 1982. The normal microbial flora. N. Engl. J. Med. 307: 83– 93.

74. MacLeod, C. M.,, R. G. Hodges,, M. Heidelberger,, and W. G. Bernhard. 1945. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82: 445– 465.

75. Mainous, A. G., III,, M. E. Evans,, W. J. Hueston,, W. B. Titlow,, and L. J. McCown. 1998. Patterns of antibiotic-resistant Streptococcus pneumoniae in children in a day-care setting. J. Fam. Pract. 46: 142– 146.

76. Malley, R.,, M. Lipsitch,, A. Stack,, R. Saladino,, G. Fleisher,, S. Pelton,, C. Thompson,, D. Briles,, and P. Anderson. 2001. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect. Immun. 69: 4870– 4873.

77. Malley, R.,, A. M. Stack,, M. L. Ferretti,, C. M. Thompson,, and R. A. Saladino. 1998. Anticapsular polysaccharide antibodies and nasopharyngeal colonization with Streptococcus pneumoniae in infant rats. J. Infect. Dis. 178: 878– 882.

78. May, R. M. 1973. Stability and Complexity in Model Ecosystems. Princeton University Press, Princeton, N.J.

79. Mbelle, N.,, R. E. Huebner,, A. D. Wasas,, A. Kimura,, I. Chang,, and K. P. Klugman. 1999. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180: 1171– 1176.

80. McCaig, L. F.,, R. E. Besser,, and J. M. Hughes. 2003. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg. Infect. Dis. 9: 432– 437.

81. McCormick, A. W.,, C. G. Whitney,, M. M. Farley,, R. Lynfield,, L. H. Harrison,, N. M. Bennett,, W. Schaffner,, A. Reingold,, J. Hadler,, P. Cieslak,, M. H. Samore,, and M. Lipsitch. 2003. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat. Med. 9: 424– 430.

82. McGee, L.,, L. McDougal,, J. Zhou,, B. G. Spratt,, F. C. Tenover,, R. George,, R. Hakenbeck,, W. Hryniewicz,, J. C. Lefévre,, A. Tomasz,, and K. P. Klugman. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network. J. Clin. Microbiol. 39: 2565– 2571.

83. McLeod, J.,, and J. Gordon. 1922. Production of hydrogen peroxide by bacteria. Biochem. J. 16: 499– 506.

84. Melander, E.,, K. Ekdahl,, G. Jonsson,, and S. Molstad. 2000. Frequency of penicillin-resistant pneumococci in children is correlated to community utilization of antibiotics. Pediatr. Infect. Dis. J. 19: 1172– 1177.

85. Melander, E.,, S. Molstad,, K. Persson,, H. B. Hansson,, M. Soderstrom,, and K. Ekdahl. 1998. Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae in children. Eur. J. Clin. Microbiol. Infect. Dis. 17: 834– 838.

86. Morita, J. Y.,, E. Kahn,, T. Thompson,, L. Laclaire,, B. Beall,, G. Gherardi,, K. L. O’Brien,, and B. Schwartz. 2000. Impact of azithromycin on oropharyngeal carriage of group A Streptococcus and nasopharyngeal carriage of macrolide-resistant Streptococcus pneumoniae. Pediatr. Infect. Dis. J. 19: 41– 46.

87. Nightingale, C. H. 1997. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr. Infect. Dis. J. 16: 438– 443.

88. Novelli, A.,, S. Fallani,, M. I. Cassetta,, S. Arrigucci,, and T. Mazzei. 2002. In vivo pharma- codynamic evaluation of clarithromycin in comparison to erythromycin. J. Chemother. 14: 584– 590.

89. Nurkka, A.,, H. Ahman,, M. Korkeila,, V. Jantti,, H. Kayhty,, and J. Eskola. 2001. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20: 25– 33.

90. Obaro, S. K.,, R. A. Adegbola,, W. A. Banya,, and B. M. Greenwood. 1996. Carriage of pneumococci after pneumococcal vaccination. Lancet 348: 271– 272.

91. O’Brien, K. L.,, L. H. Moulton,, R. Reid,, R. Weatherholtz,, J. Oski,, L. Brown,, G. Kumar,, A. Parkinson,, D. Hu,, J. Hackell,, I. Chang,, R. Kohberger,, G. Siber,, and M. Santosham. 2003. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. 362: 355– 361.

92. Pericone, C. D.,, K. Overweg,, P. W. Hermans,, and J. N. Weiser. 2000. Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect. Immun. 68: 3990– 3997.

93. Pihlajamaki, M.,, P. Kotilainen,, T. Kaurila,, T. Klaukka,, E. Palva,, and P. Huovinen. 2001. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin. Infect. Dis. 33: 483– 488.

94. Porat, N.,, G. Barkai,, M. R. Jacobs,, R. Trefler,, and R. Dagan. 2004. Four antibiotic resistant S. pneumoniae clones unrelated to the pneumococcal conjugate vaccine serotypes causing acute otitis media in southern Israel. J. Infect. Dis. 189: 385– 392.

95. Pradier, C.,, B. Dunais,, H. Carsenti-Etesse,, and P. Dellamonica. 1997. Pneumococcal resistance patterns in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 16: 644– 647.

96. Radetsky, M. S.,, G. R. Istre,, T. L. Johansen,, S. W. Parmelee,, B. A. Lauer,, A. M. Wiesenthal,, and M. P. Glode. 1981. Multiply resistant pneumococcus causing meningitis: its epidemiology within a day-care centre. Lancet ii: 771– 773.

97. Rapola, S.,, V. Jantti,, R. Haikala,, R. Syrjanen,, G. M. Carlone,, J. S. Sampson,, D. E. Briles,, J. C. Paton,, A. K. Takala,, T. M. Kilpi,, and H. Kayhty. 2000. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J. Infect. Dis. 182: 1146– 1152.

98. Regev-Yochay, G.,, M. Raz,, B. Shainberg,, R. Dagan,, M. Varon,, M. Dushenat,, and E. Rubinstein. 2003. Independent risk factors for carriage of penicillin-non-susceptible Streptococcus pneumoniae. Scand. J. Infect. Dis. 35: 219– 222.

99. Reichler, M. R.,, A. A. Allphin,, R. F. Breiman,, J. R. Schreiber,, J. E. Arnold,, L. K. McDougal,, R. R. Facklam,, B. Boxerbaum,, D. May,, R. O. Walton,, and M. R. Jacobs. 1992. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J. Infect. Dis. 166: 1346– 1353.

100. Rieux, V.,, C. Carbon,, and E. Azoulay- Dupuis. 2001. Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae. J. Infect. Dis. 184: 66– 72.

101. Robins-Browne, R. M.,, A. B. Kharsany,, and H. J. Koornhof. 1984. Antibiotic-resistant pneumococci in hospitalized children. J. Hyg. 93: 9– 16.

102. Samore, M. H.,, M. K. Magill,, S. C. Alder,, E. Severina,, L. Morrison-De Boer,, J. L. Lyon,, K. Carroll,, J. Leary,, M. B. Stone,, D. Bradford,, J. Reading,, A. Tomasz,, and M. A. Sande. 2001. High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. Pediatrics 108: 856– 865.

103. Schrag, S. J.,, C. Pena,, J. Fernandez,, J. Sanchez,, V. Gomez,, E. Perez,, J. M. Feris,, and R. E. Besser. 2001. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286: 49– 56.

104. Simell, B.,, M. Korkeila,, H. Pursiainen,, T. M. Kilpi,, and H. Kayhty. 2001. Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin, and pneumococcal surface protein a in children. J. Infect. Dis. 183: 887– 896.

105. Spratt, B. G.,, and B. M. Greenwood. 2000. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 356: 1210– 1211.

106. Steinman, M. A.,, R. Gonzales,, J. A. Linder,, and C. S. Landefeld. 2003. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann. Intern. Med. 138: 525– 533.

107. Syrogiannopoulos, G. A.,, I. N. Grivea,, T. A. Davies,, G. D. Katopodis,, P. C. Appelbaum,, and N. G. Beratis. 2000. Antimicrobial use and colonization with erythromycin-re- sistant Streptococcus pneumoniae in Greece during the first 2 years of life. Clin. Infect. Dis. 31: 887– 893.

108. Tsolia, M.,, G. Kouppari,, A. Zaphiropoulou,, S. Gavrili,, M. Tsirepa,, D. Kafetzis,, and T. Karpathios. 1999. Prevalence and patterns of resistance of Streptococcus pneumoniae strains isolated from carriers attending day care centers in the area of Athens. Microb. Drug Resist. 5: 271– 278.

109. Ussery, X. T.,, B. D. Gessner,, H. Lipman,, J. A. Elliott,, M. J. Crain,, P. C. Tien,, A. J. Parkinson,, M. Davidson,, R. R. Facklam,, and R. F. Breiman. 1996. Risk factors for nasopharyngeal carriage of resistant Streptococcus pneumoniae and detection of a multiply resistant clone among children living in the Yukon- Kuskokwim Delta region of Alaska. Pediatr. Infect. Dis. J. 15: 986– 992.

110. Veenhoven, R.,, D. Bogaert,, C. Uiterwaal,, C. Brouwer,, H. Kiezebrink,, J. Bruin,, E. IJzerman,, P. Hermans,, R. de Groot,, B. Zegers,, W. Kuis,, G. Rijkers,, A. Schilder,, and E. Sanders. 2003. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomized study. Lancet 361: 2189– 2195.

111. Weiser, J. N.,, D. Bae,, C. Fasching,, R. W. Scamurra,, A. J. Ratner,, and E. N. Janoff. 2003. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc. Natl. Acad. Sci. USA 100: 4215– 4220.

112. Whitney, C. G.,, M. M. Farley,, J. Hadler,, L. H. Harrison,, N. M. Bennett,, R. Lynfield,, A. Reingold,, P. R. Cieslak,, T. Pilishvili,, D. Jackson,, R. R. Facklam,, J. H. Jorgensen,, and A. Schuchat. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348: 1737– 1746.

113. Whitney, C. G.,, M. M. Farley,, J. Hadler,, L. H. Harrison,, C. Lexau,, A. Reingold,, L. Lefkowitz,, P. R. Cieslak,, M. Cetron,, E. R. Zell,, J. H. Jorgensen,, and A. Schuchat. 2000. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343: 1917– 1924.

114. Yagupsky, P.,, N. Porat,, D. Fraser,, F. Prajgrod,, M. Merires,, L. McGee,, K. P. Klugman,, and R. Dagan. 1998. Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel. J. Infect. Dis. 177: 1003– 1012.

115. Yeh, S. H.,, K. M. Zangwill,, H. Lee,, S. J. Chang,, V. I. Wong,, D. P. Greenberg,, and J. I. Ward. 2003. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants. Vaccine 21: 2627– 2631.

Tables

Changing the Ecology of Pneumococci with Antibiotics and Vaccines

/content/10.1128/9781555816537.chap18.tab18-1

TABLE 1

Observation studies of the association between antibiotic used and carriage of antibiotic-nonsusceptible S. pneumoniae a

10.1128/9781555816537/tab18-1_thmb.gif

10.1128/9781555816537/tab18-1.gif

TABLE 1

Observation studies of the association between antibiotic used and carriage of antibiotic-nonsusceptible S. pneumoniae a

/content/10.1128/9781555816537.chap18.tab18-2

TABLE 2

Prospective studies of the effect of antibiotics on carriage of antibiotic-resistant S. pneumoniae comparing carriage before treatment to carriage during and immediately after treatment a

10.1128/9781555816537/tab18-2_thmb.gif

10.1128/9781555816537/tab18-2.gif

TABLE 2

Prospective studies of the effect of antibiotics on carriage of antibiotic-resistant S. pneumoniae comparing carriage before treatment to carriage during and immediately after treatment a

/content/10.1128/9781555816537.chap18.tab18-3

TABLE 3

Studies on the effect of conjugate pneumococcal vaccine on carriage of S. pneumoniae and antibiotic-resistant S. pneumoniae

10.1128/9781555816537/tab18-3_thmb.gif

10.1128/9781555816537/tab18-3.gif

TABLE 3

Studies on the effect of conjugate pneumococcal vaccine on carriage of S. pneumoniae and antibiotic-resistant S. pneumoniae